The future of Cell and Gene Therapy (CGT) holds immense promise, but the path forward involves navigating a complex and evolving investment landscape. Recently, IBTV hosted a spotlight panel discussion on the Investment Landscape for 2025, bringing together industry leaders to share their predictions and expectations. Among the panelists was Tony Pare, CEO of Title21 Health Solutions. The discussion covered key trends, investment drivers, geographic shifts, the role of vendors, and the impact of regulatory changes on the CGT sector.
Navigating Investment in a Shifting Landscape
Panelists discussed how the focus in CGT has shifted from purely scientific breakthroughs to manufacturing feasibility and, increasingly, commercial viability and patient accessibility.
Tony Pare highlighted that investors carefully evaluate which companies are positioned for long-term success before committing capital. “Investors, what they’re looking for is who will survive? In terms of, who’s going to be the manufacturers, who’s going to support the biotherapy companies, before they make that bet.” He noted that factors like a company’s product maturity, financial stability, and ability to “weather the storm” without needing immediate investment are crucial.
The Role of Standardization and Flexibility
When discussing the role vendors play, Tony emphasized the unique position of technology providers like Title21. He pointed out the need for adaptable systems in manufacturing environments handling diverse protocols, while also advocating for greater standardization in core processes and training. “As a vendor to folks that manufacture, I think where we can help is standardization plus flexibility.”
Regulatory Optimism and Future Directions
Addressing regulatory impacts, Tony shared an optimistic outlook based on recent interactions concerning the FDA’s approach. He noted the increasing rate of product approvals and the potential benefits of a platform-based approach for validating manufacturing processes, which could streamline development.
Looking ahead, Tony identified a key trend for 2025 and beyond: the move towards more standardized manufacturing practices. He stressed the importance of involving manufacturing experts early on, shifting the focus from purely scientific development to robust, scalable production.
Watch the Full Discussion
Gain deeper insights into the future of CGT investment by watching the complete IBTV panel discussion featuring Tony Pare and other industry leaders below.
